Courtesy of Benzinga.
Shares of United Therapeutics (NASDAQ: UTHR) are trading sharply higher on news that patent infringement ruling against competitor Sandoz.
The ruling disallows Sandoz to sell the generic version of United Therapeutics hypertension drug Remodulin before 2017.
Shares were trading up more than 24 percent to $114.47.